Washington Trust’s SELLAS Life Sciences SLS Stock Holding History

Washington Trust’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1	Closed	–	–	984
2020 Q1	$0	Buy	+1	New	+$3	﹤0.01%	968
2018 Q3	–	Sell	-1	Closed	–	–	708
2018 Q2	$0	Buy	+1	New	+$274	﹤0.01%	966

Other funds holding SLS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Washington Trust's SLS Position: Q2 2020 in Review

Washington Trust sold out of SELLAS Life Sciences (SLS) in Q2 2020, closing a stake of 1 share.

Washington Trust first reported a position in SLS in Q2 2018 and held it in 2 quarters. The position peaked at $0 in Q1 2020. 16 funds tracked by Wall St. Rank hold SLS as of Q2 2020.

Washington Trust reported no remaining SELLAS Life Sciences position as of Q2 2020 after selling out during the quarter.
Washington Trust sold 1 SELLAS Life Sciences share in Q2 2020.
Washington Trust first reported a position in SELLAS Life Sciences in Q2 2018 and held it in 2 quarters.
Washington Trust's SELLAS Life Sciences position peaked at $0 in Q1 2020.
16 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2020.

Based on Washington Trust's 13F filing for Q2 2020, filed 4 Aug 2020.